Ashkenazi Jewish Genetic Diseases Panel

Ashkenazi Jewish Diseases, 16 Genes 0051415
Method: Polymerase Chain Reaction/Fluorescence Monitoring

Preferred gene panel for carrier screening for individuals of Ashkenazi Jewish descent considering pregnancy or currently pregnant

Detect 51 variants associated with 16 disorders common in individuals of Ashkenazi Jewish descent

Cystic Fibrosis (CFTR) 165 Pathogenic Variants 2013661
Method: Polymerase Chain Reaction/Fluorescence Monitoring

Carrier screening for expectant individuals and those planning a pregnancy AND diagnostic testing for individuals with symptoms of classic CF

Not included in prenatal screening panel for individuals of Ashkenazi Jewish descent

Individuals of Ashkenazi Jewish descent are at an increased risk for certain autosomal recessive genetic disorders. An estimated one in every four or five individuals of Ashkenazi Jewish descent is a carrier for one of these disorders.  In combination, the Ashkenazi Jewish Disease Panel and Cystic Fibrosis 165 Pathogenic Variants tests screen for all of the disorders that the American College of Medical Genetics and Genomics (ACMG) and the American College of Obstetrics and Gynecology (ACOG) recommend testing for in individuals of Ashkenazi Jewish descent.

Disease Overview

Screening

  • Routine preconception or prenatal carrier screening for genetic diseases common in individuals of Ashkenazi Jewish descent is recommended by:
    • ACOG 
      • ABCC8-related hyperinsulinemia
      • Bloom syndrome
      • Canavan disease
      • Cystic fibrosis
      • Fanconi anemia group C
      • Familial dysautonomia
      • Gaucher disease
      • Glycogen storage disease type 1A
      • Joubert syndrome type 2
      • Maple syrup urine disease type 1B
      • Mucolipidosis type IV
      • Niemann-Pick type A
      • Tay-Sachs disease
      • Usher syndrome (type 1F and type 3)
    • ACMG for nine of the disorders described in the ACOG guidelines 
  • Screening for a specific disorder may be offered to individuals not of Ashkenazi Jewish descent, including:
    • Relatives who carry one or more variants included in the test
    • Reproductive partners who are carriers of one of the panel disorders, although detection rates for non-Ashkenazi individuals is variable by disorder and largely unknown

For additional clinical information and the carrier frequency of diseases included on the Ashkenazi Jewish Diseases, 16 Genes panel, see the Ashkenazi Jewish Genetic Diseases Consult topic.

Genetics

Inheritance

Autosomal recessive

Genes/Variants

See Clinical Sensitivity table

Test Interpretation

Analytical sensitivity/specificity: 99%

Clinical Sensitivity for Individuals of Ashkenazi Jewish Descent
Disease (and Associated Gene) Variants Tested (HGVS Nomenclature) Variants Tested (Legacy Nomenclature) Clinical Sensitivity in Individuals of Ashkenazi Jewish Descent Clinical Sensitivity in non-Ashkenazi Jewish Individuals Carrier Risk After Negative Test for Ashkenazi Jewish Individuals

ABCC8-related hyperinsulinism (ABCC8)

p.F1388del (c.4163_4165del)

p.V187D (c.560T>A)

c.3992-9G>A

n/a

97% 

Unknown

1/1,700

Bloom syndrome (BLM)

p.Y736Lfs (c.2207_2212delinsTAGATTC)

2281del6/ins7

97% 

~3%

1/3,300

Canavan disease (ASPA)

c.433-2A>G

p.Y231X (c.693C>A)

p.E285A (c.854A>C)

p.A305E (c.914C>A)

n/a

99% 

55%

1/4,900

Familial dysautonomia (IKBKAP)

p.R696P (c.2087G>C)

c.2204+6T>C

 

IVS20+6T>C

99% 

Unknown

1/3,100

Fanconi anemia group C (FANCC)

p.D23Ifs (c.67delG)

c.456+4A>T

322delG

IVS4+4A>T

99% 

Unknown

1/8,800

Gaucher disease (GBA)

p.L29Afs (c.84dupG)

c.115+1G>A

p.N409S (c.1226A>G)

c.1263_1317del55

p.V433L (c.1297G>T)

p.D448H (c.1342G>C)

p.L483P (c.1448T>C)

p.R535H (c.1604G>A)

84G>GG

IVS2+1G>A

N370S

del55bp

V394L

D409H

L444P

R496H

90% 

55%

1/140

Glycogen storage disease type 1A (G6PC)

p.Q27Rfs (c.79delC)

p.Y128Tfs (c.379_380dupTA)

p.R83H (c.248G>A)

p.R83C (c.247C>T)

p.G188R (c.562G>C)

p.Q242X (c.724C>T)

p.Q347X (c.1039C>T)

p.G270V (c.809G>T)

p.F327del (c.979_981delTTC)

n/a

99% 

Varies by ethnicity

1/7,000

Joubert syndrome type 2 (TMEM216)

p.R73L (c.218G>T)

n/a

99% 

Unknown

1/9,100

Lipoamide dehydrogenase deficiency (DLD)

p.Y35X (c.104dupA)

p.G229C (c.685G>T)

n/a

99% 

Unknown

1/9,300

Maple syrup urine disease type 1B (BCKDHB)

p.R183P (c.548G>C)

p.G278S (c.832G>A)

p.E372X (c.1114G>T)

n/a

99% 

Unknown

1/11,000

Mucolipidosis type IV (MCOLN1)

c.406-2A>G

g.511_6943del

IVS3-2A>G

del6.4kb

95% 

6-10%

1/2,500

NEB-related nemaline myopathy (NEB)

exon 55 del (p.R2478_D2512del)

n/a

99% 

Unknown

1/10,700

Niemann-Pick disease type A (SMPD1)

p.L304P (c.911T>C)

p.F333Sfs (c.996delC)

p.R498L (c.1493G>T)

p.R610del (c.1829_1831delGCC)

L302P

fsP330

R496L

R608del

90% 

Varies by ethnicity

1/900

Tay-Sachs disease (HEXA)a

7.6 kb del

p.G269S (c.805G>A)

c.1073+1G>A

p.Y427Ifs (c.1274_1277dup TATC)

c.1421+1G>C

Pseudodeficiency alleles:

p.R247W (c.739C>T)

p.R249W (c.745C>T)

IVS9+1G>A

1278dupTATC

IVS12+1G>C

94% 

59%

1/480

Usher syndrome type 1F (PCDH15)

p.R245X (c.733C>T)

n/a

62% 

Unknown

1/190

Usher syndrome type 3 (CLRN1)

p.N48K (c.144T>G)

n/a

98%  

Unknown

1/7,000

aFor specific Tay-Sachs disease testing, see the Tay-Sachs Disease Testing fact sheet

n/a, not applicable

Results

  • Positive: one pathogenic variant detected
    • Individual is a carrier of the associated disease
    • Screening for that disease should be offered to the individual’s reproductive partner
    • Genetic counseling is recommended
  • Negative: no targeted pathogenic variants identified
    • For residual carrier risk estimates, see the Clinical Sensitivity table

Limitations

  • Variants other than those tested on this panel will not be detected
  • Diagnostic errors can occur due to rare sequence variations
References 
  1. ACOG Committee on Genetics. Committee Opinion No. 690 Summary: Carrier Screening in the Age of Genomic Medicine. Obstet Gynecol. 2017; 129(3): 595-596. PubMed
  2. ACOG Committee on Genetics. ACOG Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol. 2017; 129(3): e41-e55. PubMed
  3. Gross SJ, Pletcher BA, Monaghan KG, Professional Practice and Guidelines Committee, American College of Medical Genetics and Genomics. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008; 10(1): 54-6. [Reaffirmed 2013]. PubMed
  4. Glaser B, Blech I, Krakinovsky Y, Ekstein J, Gillis D, Mazor-Aronovitch K, Landau H, Abeliovich D. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genet Med. 2011; 13(10): 891-4. PubMed
  5. German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat. 2007; 28(8): 743-53. PubMed
  6. Matalon R, Delgado L, Michals-Matalon K. Canavan Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Sep 2018; Accessed: Jul 2019]
  7. Pastores G, Hughes D. Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Jun 2018; Accessed: Jul 2019]
  8. Ekstein J, Rubin BY, Anderson SL, Weinstein DA, Bach G, Abeliovich D, Webb M, Risch N. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A. 2004; 129A(2): 162-4. PubMed
  9. Edvardson S, Shaag A, Zenvirt S, Erlich Y, Hannon GJ, Shanske AL, Gomori JM, Ekstein J, Elpeleg O. Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is associated with a TMEM216 mutation. Am J Hum Genet. 2010; 86(1): 93-7. PubMed
  10. Shaag A, Saada A, Berger I, Mandel H, Joseph A, Feigenbaum A, Elpeleg ON. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet. 1999; 82(2): 177-82. PubMed
  11. Edelmann L, Wasserstein MP, Kornreich R, Sansaricq C, Snyderman SE, Diaz GA. Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. Am J Hum Genet. 2001; 69(4): 863-8. PubMed
  12. Schiffmann R, Grishchuk Y, Goldin E. Mucolipidosis IV. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last updated: Jul 2015; Accessed: Jul 2019]
  13. Anderson SL, Ekstein J, Donnelly MC, Keefe EM, Toto NR, LeVoci LA, Rubin BY. Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene. Hum Genet. 2004; 115(3): 185-90. PubMed
  14. Wasserstein M, Schuchman E. Acid Sphingomyelinase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last updated: Jun 2015; Accessed: Jul 2019]
  15. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 1993; 270(19): 2307-15. PubMed
  16. Ben-Yosef T, Ness SL, Madeo AC, Bar-Lev A, Wolfman JH, Ahmed ZM, Desnick RJ, Willner JP, Avraham KB, Ostrer H, Oddoux C, Griffith AJ, Friedman TB. A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N Engl J Med. 2003; 348(17): 1664-70. PubMed
  17. Fields RR, Zhou G, Huang D, Davis JR, Möller C, Jacobson SG, Kimberling WJ, Sumegi J. Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations. Am J Hum Genet. 2002; 71(3): 607-17. PubMed
  18. Ness SL, Ben-Yosef T, Bar-Lev A, Madeo AC, Brewer CC, Avraham KB, Kornreich R, Desnick RJ, Willner JP, Friedman TB, Griffith AJ. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. J Med Genet. 2003; 40(10): 767-72. PubMed
  19. Bali DS, Chen Y, Austin S, Goldstein JL. Glycogen Storage Disease Type I. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. University of Washington, 1993-2019. Seattle WA [Last Update: Aug 2016; Accessed: Jul 2019]
  20. Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, Schneider A, Stoll K, Wapner R, Watson MS. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015; 125(3): 653-62. PubMed
  21. Gills D. Familial Hyperinsulinism. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Mar 2019; Accessed: Jul 2019]
  22. Kaback M, Desnick R. Hexosaminidase A Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Aug 2011; Accessed: Jul 2019]
  23. Lentz J, Keats B. Usher Syndrome Type I. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. University of Washington, 1993-2019. Seattle, WA [Last updated: May 2016; Accessed: Jul 2019]
  24. North K, Ryan M. Nemaline Myopathy. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. University of Washington, 1993-2019. Seattle, WA [Last updated: Jun 2015; Accessed: Jul 2019]
  25. Mehta PA, Tolar J. Fanconi Anemia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Revision: Mar 2018; Accessed: Jul 2019]
  26. Parisi M, Glass I. Joubert Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Jun 2017; Accessed: Jul 2019]
  27. Quinonez S, Thoene J. Dihydrolipoamide Dehydrogenase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. University of Washington, 1993-2019. Seattle, WA [Accessed: Jul 2019]
  28. Flanagan M, Cunniff CM. Bloom Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Feb 2019; Accessed: Jul 2019]
  29. Shohat M, Hubshman M. Familial Dysautonomia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews,. Seattle, WA [Last Update: Dec 2014; Accessed: Jul 2019]
  30. Strauss K, Puffenberger G, Morton D. Maple Syrup Urine Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. University of Washington, 1993-2019. Seattle, WA [Last updated: May 2013; Accessed: Jul 2019]

Last Update: August 2019